EMERGENT BIOSOLUTIONS INC. Proceeds from Lines of Credit
EMERGENT BIOSOLUTIONS INC. (EBS) reported Proceeds from Lines of Credit of $0 for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-11-06.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromLinesOfCredit · last filed 2020-11-06
- EMERGENT BIOSOLUTIONS INC. proceeds from lines of credit for the quarter ending 2020-09-30 was $0.00.
- EMERGENT BIOSOLUTIONS INC. proceeds from lines of credit for the quarter ending 2020-06-30 was $0.00, a 100.00% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. proceeds from lines of credit for the quarter ending 2020-03-31 was $0.00, a 100.00% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. proceeds from lines of credit for the quarter ending 2019-09-30 was $0.00.
| Period end | Proceeds from Lines of Credit 3 month | Proceeds from Lines of Credit 6 month | Proceeds from Lines of Credit 9 month |
|---|---|---|---|
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $0.00 derived: sum of 2 quarters · filed 2020-11-06 | $0.00 10-Q · filed 2020-11-06 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31 | $0.00 10-Q · filed 2020-07-31 | |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-01 | ||
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $100.00M derived: sum of 2 quarters · filed 2020-11-06 | $130.00M 10-Q · filed 2020-11-06 |
| 2019-06-30 | $100.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31 | $130.00M 10-Q · filed 2020-07-31 | |
| 2019-03-31 | $30.00M 10-Q · filed 2020-05-01 | ||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $0.00 derived: sum of 2 quarters · filed 2019-11-07 | $0.00 10-Q · filed 2019-11-07 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-02 | $0.00 10-Q · filed 2019-08-02 | |
| 2018-03-31 | $0.00 10-Q · filed 2019-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |